Objectives We critically evaluated the quality of evidence and quality of harm reporting in clinical trials that evaluated the effectiveness of hydroxychloroquine (HCQ) or chloroquine (CQ) for the treatment of coronavirus disease 2019 (COVID-19). Study design and setting Scientific databases were systematically searched to identify relevant trials of HCQ/CQ for the treatment of COVID-19 published up to 10 September 2020. The Cochrane risk-of-bias tools for randomized trials and non-randomized trials of interventions were used to assess risk of bias in the included studies. A 10-item Consolidated Standards of Reporting Trials (CONSORT) harm extension was used to assess quality of harm reporting in the included trials. Results Sixteen trials, including fourteen randomized trials and two non-randomized trials, met the inclusion criteria. The results from the included trials were conflicting and lacked effect estimates adjusted for baseline disease severity or comorbidities in many cases, and most of the trials recruited a fairly small cohort of patients. None of the clinical trials met the CONSORT criteria in full for reporting harm data in clinical trials. None of the 16 trials had an overall ‘low’ risk of bias, while four of the trials had a ‘high’, ‘critical’, or ‘serious’ risk of bias. Biases observed in these trials arise from the randomization process, potential deviation from intended interventions, outcome measurements, selective reporting, confounding, participant selection, and/or classification of interventions. Conclusion In general, the quality of currently available evidence for the effectiveness of CQ/HCQ in patients with COVID-19 is suboptimal. The importance of a properly designed and reported clinical trial cannot be overemphasized amid the COVID-19 pandemic, and its dismissal could lead to poorer clinical and policy decisions, resulting in wastage of already stretched invaluable health care resources.

Use of hydroxychloroquine and chloroquine in COVID-19: How good is the quality of randomized controlled trials? / F. Mazhar, M.A. Hadi, C.S. Kow, A.M.N. Marran, H.A. Merchant, S.S. Hasan. - In: INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. - ISSN 1201-9712. - 101(2020 Dec), pp. 107-120. [10.1016/j.ijid.2020.09.1470]

Use of hydroxychloroquine and chloroquine in COVID-19: How good is the quality of randomized controlled trials?

F. Mazhar
Primo
Conceptualization
;
2020

Abstract

Objectives We critically evaluated the quality of evidence and quality of harm reporting in clinical trials that evaluated the effectiveness of hydroxychloroquine (HCQ) or chloroquine (CQ) for the treatment of coronavirus disease 2019 (COVID-19). Study design and setting Scientific databases were systematically searched to identify relevant trials of HCQ/CQ for the treatment of COVID-19 published up to 10 September 2020. The Cochrane risk-of-bias tools for randomized trials and non-randomized trials of interventions were used to assess risk of bias in the included studies. A 10-item Consolidated Standards of Reporting Trials (CONSORT) harm extension was used to assess quality of harm reporting in the included trials. Results Sixteen trials, including fourteen randomized trials and two non-randomized trials, met the inclusion criteria. The results from the included trials were conflicting and lacked effect estimates adjusted for baseline disease severity or comorbidities in many cases, and most of the trials recruited a fairly small cohort of patients. None of the clinical trials met the CONSORT criteria in full for reporting harm data in clinical trials. None of the 16 trials had an overall ‘low’ risk of bias, while four of the trials had a ‘high’, ‘critical’, or ‘serious’ risk of bias. Biases observed in these trials arise from the randomization process, potential deviation from intended interventions, outcome measurements, selective reporting, confounding, participant selection, and/or classification of interventions. Conclusion In general, the quality of currently available evidence for the effectiveness of CQ/HCQ in patients with COVID-19 is suboptimal. The importance of a properly designed and reported clinical trial cannot be overemphasized amid the COVID-19 pandemic, and its dismissal could lead to poorer clinical and policy decisions, resulting in wastage of already stretched invaluable health care resources.
English
Settore BIO/14 - Farmacologia
Review essay
Esperti anonimi
Ricerca applicata
Pubblicazione scientifica
dic-2020
Elsevier
101
107
120
14
Pubblicato
Periodico con rilevanza internazionale
crossref
Aderisco
info:eu-repo/semantics/article
Use of hydroxychloroquine and chloroquine in COVID-19: How good is the quality of randomized controlled trials? / F. Mazhar, M.A. Hadi, C.S. Kow, A.M.N. Marran, H.A. Merchant, S.S. Hasan. - In: INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. - ISSN 1201-9712. - 101(2020 Dec), pp. 107-120. [10.1016/j.ijid.2020.09.1470]
open
Prodotti della ricerca::01 - Articolo su periodico
6
262
Article (author)
no
F. Mazhar, M.A. Hadi, C.S. Kow, A.M.N. Marran, H.A. Merchant, S.S. Hasan
File in questo prodotto:
File Dimensione Formato  
HCQ COVID.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 1.07 MB
Formato Adobe PDF
1.07 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/814028
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 8
social impact